Elevance Health (NYSE:ELV) Full Year 2024 Results

Key Financial Results

• Revenue: US$176.8b (up 3.2% from FY 2023).
• Net income: US$5.98b (flat on FY 2023).
• Profit margin: 3.4% (down from 3.5% in FY 2023). The decrease in margin was driven by higher expenses.
• EPS: US$25.81.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Elevance Health EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.2%.

The primary driver behind last 12 months revenue was the Health Benefits segment contributing a total revenue of US$150.3b (85% of total revenue). Notably, cost of sales worth US$127.6b amounted to 72% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$39.5b (91% of total expenses). Explore how ELV's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Healthcare industry in the US.

The company's shares are down 1.1% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Elevance Health's balance sheet health.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.